Please see Important Safety Information and Indication(s) on the next page.
Please see full Prescribing Information with Medication Guide available at http://www1.astrazeneca-us.com/pi/symbicort.pdf
For more information, visit our Web site at SYMBICORT TouchPoints.com.
SYMBICORT is indicated for the treatment of asthma in patients 12 years and older (also see Boxed WARNING).
SYMBICORT 160/4.5 is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
SYMBICORT is NOT indicated for the relief of acute bronchospasm.
Please see full Prescribing Information, including Boxed WARNING and Medication Guide.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
SYMBICORT is a registered trademark and AZ&me is a trademark of the AstraZeneca group of companies.
©2014 AstraZeneca. All rights reserved. 986503-2952300 Last Updated 1/14